ORIGINAL RESEARCH article

Front. Oncol.

Sec. Cancer Epidemiology and Prevention

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1480942

Strategies to Accelerate Cervical Cancer Elimination in Greece: A Modeling Study

Provisionally accepted
Cody  PalmerCody Palmer1*Anastasios  SkroumpelosAnastasios Skroumpelos2Ugne  SabaleUgne Sabale3Ilias  GountasIlias Gountas2Georgios  TrimisGeorgios Trimis2Antonis  KarokisAntonis Karokis2Theodoros  AgorastosTheodoros Agorastos4
  • 1Merck & Co., Inc., Kenilworth, United States
  • 2MSD Greece, Athens, Greece
  • 3MSD Lithuania, Vilnius, Lithuania
  • 4Aristotle University of Thessaloniki, Thessaloniki, Central Macedonia, Greece

The final, formatted version of the article will be published soon.

Introduction: Most cervical cancer cases are caused by human papillomavirus (HPV), a vaccine-preventable infection. According to the World Health Organization (WHO), both high HPV vaccination coverage and cervical cancer screening rates will accelerate the elimination of cervical cancer, a threshold defined as <4 age-standardized cases per 100,000 women.Methods: A dynamic transmission model was used to study the effect of increased HPV vaccination coverage and cervical cancer screening rates in Greece on cervical cancer incidence over a 100-year time horizon. Greek-specific or proxy data were used for both model inputs and calibration prior to the evaluation of eight different vaccination and screening scenarios. The estimated time to cervical cancer elimination and eradication in Greece was reported as the year each scenario reached 4 cases per 100,000 and <1 case per 100,000, respectively.Results: Greece reached the WHO cervical cancer elimination threshold by 2074 with a 50% HPV vaccination coverage and 50% Pap test screening rate. When HPV DNA-based methods replaced Pap tests at the same rate and HPV vaccination coverage levels, the WHO threshold was reached by 2061. Other scenarios modeled future changes in HPV DNA-based screening rates with either 50% or 90% vaccination coverage. The 75% HPV DNA-based screening with 90% vaccination coverage scenario reached the WHO threshold by 2047 and the eradication threshold before the end of the century (2096).Conclusion: If public health interventions are implemented to accelerate HPV vaccination coverage and HPV DNA-based screening adherence within the next five years, Greece can reach the WHO’s cervical cancer elimination threshold by 2047 and eradicate cervical cancer before the end of the century.

Keywords: cervical cancer, Human papillomavirus vaccine, HPV, HPV DNA, screening, nonavalent, 9-Valent, Greece

Received: 18 Dec 2024; Accepted: 21 Apr 2025.

Copyright: © 2025 Palmer, Skroumpelos, Sabale, Gountas, Trimis, Karokis and Agorastos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Cody Palmer, Merck & Co., Inc., Kenilworth, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.